MicroCures has built a broad pipeline of novel therapeutic programs based on the company’s proprietary cell migration modulation platform.
The company’s cell movement acceleration programs are focused on excisional wound repair, dermal burn repair, corneal burn repair and cavernous nerve repair/regeneration, among others. Earlier-stage cell movement deceleration programs are being developed to combat cancer metastases and fibrosis.
|MCR- 231 Neurotrophic Keratitis/Corneal Burn Wounds||Lead indication, Planned IND submission in 2023, Phase 1 trial pending IND||Preclinical studies demonstrated significantly improved tissue repair, nerve repair, and ocular function||read more »|
|MCR- 420 Cavernous Nerve Repair||Preclinical studies ongoing||Preclinical studies demonstrated significantly improved erectile response||read more »|
|MCR-033 Central Nerve/ Spinal Cord Regeneration||Preclinical studies ongoing||Preclinical studies demonstrated significantly improved movement and function||read more »|
|MCR 111- Dermal damage: excision, burn, and abrasion||Planned IND filing and initiation of Phase 1 trials in 2024||Preclinical studies demonstrated significantly improved speed and quality of tissue repair||read more »|
|Cardiac Repair||Preclinical studies ongoing||Preclinical studies demonstrated significantly improved tissue repair and cardiac function||read more »|